Cargando…
Abemaciclib does not increase the corrected QT interval in healthy participants
Abemaciclib is an orally administered, potent, and selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6, approved for advanced or metastatic breast cancer. This study aimed to use an exposure–response approach to investigate the effect of abemaciclib and its active metabolites (M2...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499409/ https://www.ncbi.nlm.nih.gov/pubmed/37337637 http://dx.doi.org/10.1111/cts.13573 |